Koninklijke DSM NV (KDSKF.PK)

KDSKF.PK on OTC Markets Group - US Other OTC and Grey Market

68.70USD
28 Mar 2014
Price Change (% chg)

$4.70 (+7.34%)
Prev Close
$64.00
Open
$68.70
Day's High
$68.70
Day's Low
$68.70
Volume
425
Avg. Vol
286
52-wk High
$79.50
52-wk Low
$61.35

KDSKF.PK

Chart for KDSKF.PK

About

Koninklijke DSM NV is a Netherlands-based science company, which is active in health, nutrition and materials sectors. It operates within three main business areas, namely Life Sciences, Materials Sciences and Innovation Center. The Life Sciences area comprises such segments, as Nutrition, which serves the food and beverage,... (more)

Overall

Beta: 0.98
Market Cap (Mil.): €9,002.31
Shares Outstanding (Mil.): 181.43
Dividend: 1.15
Yield (%): 3.33

Financials

  KDSKF.PK Industry Sector
P/E (TTM): 20.74 15.18 27.85
EPS (TTM): 2.39 -- --
ROI: 4.89 6.24 15.20
ROE: 6.99 6.32 17.37
Search Stocks

BRIEF-DSM in exclusive talks to buy vitamin C producer Aland

* Further information will be announced in due course, if and when appropriate

09 Apr 2014

POET-DSM says Iowa cellulosic ethanol plant running by June

Feb 18 - An Iowa ethanol plant that will be one of the first producers of biofuels made from crop waste will be operating by June, a general manager of the plant said in an interview on Tuesday.

19 Feb 2014

EU mergers and takeovers (Feb 6)

BRUSSELS, Feb 6 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

06 Feb 2014

UPDATE 1-DSM's 2013 core earnings fall short of target

AMSTERDAM, Jan 21 - Dutch food and chemicals group DSM fell short of its target for full-year core earnings due to weakness in its nutrition business and adverse exchange rates and said it expects this year to remain tough.

21 Jan 2014

DSM's 2013 core earnings fall short of target

AMSTERDAM, Jan 21 - Dutch food and chemicals group DSM reported on Tuesday full-year core earnings of 1.31 billion euros ($1.78 billion), falling short of target because of weakness in its nutrition business and adverse exchange rates.

21 Jan 2014

EU mergers and takeovers (Jan 10)

BRUSSELS, Jan 10 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

10 Jan 2014

JLL sees roll-up potential for pharma services after $2.6 billion deal

Nov 21 (Buyouts Magazine) - JLL Partners co-founder Paul S. Levy is expecting more acquisitions after the firm closed a $2.6 billion carve-out transaction to combine its Patheon Inc portfolio company with Dutch-based DSM's pharmaceutical unit.

21 Nov 2013

JLL sees roll-up potential for pharma services after $2.6B deal

Nov 21 (Buyouts Magazine) - JLL Partners co-founder Paul S. Levy is expecting more acquisitions after the firm closed a $2.6 billion carve-out transaction to combine its Patheon Inc portfolio company with Dutch-based DSM's pharmaceutical unit.

21 Nov 2013

DSM to fold pharma arm into venture with private equity firm

AMSTERDAM/TORONTO - Dutch food and chemicals group DSM will spin off its pharmaceuticals unit into a new joint venture majority-owned by private equity firm JLL Partners as the company shifts its focus toward higher-margin products.

20 Nov 2013

UPDATE 3-DSM to fold pharma arm into venture with private equity firm

(Adds details from conference call, analyst comment, share price move)

20 Nov 2013

Earnings vs. Estimates

Search Stocks